SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
PHIO

Phio Pharmaceuticals Corp. (PHIO)

NASDAQ: PHIO · USD
Healthcare · Biotechnology
$0.66-$0.06 (-8.25%)
 
Market cap
$7.84M
Insider Score
Analyst consensus
Market Cap$7.84M-39.9%
Revenue (ttm)n/a
Net Income-$14.67M
EPS-$1.19
Shares Out11.95M
PE Ration/a
Forward PE-0.90
Dividendn/a
Ex-Dividend Daten/a
Volume145,405
Open$0.73
Previous Close$0.71
Day's Range$0.64 - $0.73
52-Week Range$0.64 - $1.88
Beta0.92
AnalystsStrong Buy
Price Target$14.00(+2034.15%)
Earnings Daten/a
-7.69% (1D)
No price history available.

About PHIO

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.

Address
411 Swedeland Road, King of Prussia, PA, 19406, United States
Market Cap
8 million
Employees
6
Industrial Classification
Biotechnology

Phio Pharmaceuticals Corp. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
81st Percentile Overall Score
PHIO InsiderScore:88 / 99

Phio Pharmaceuticals Corp. scored higher than 81% of companies evaluated by InsiderBuying, and ranked 15th out of 96 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Phio Pharmaceuticals Corp. bought $104.8K of stock across 11 purchases in the last 90 days, the largest of them $20.5K.

Stake Increase

The average purchase added about 17% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

1 of these purchases was made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$146.83K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy0 Hold0 Sell

1 firm rating PHIO in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
-0.69%
5 Days
-11.95%
1 Month
-20.11%
6 Months
-34.40%
1 Year
-39.92%

$PHIO stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in PHIO holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by PHIO's directors and management

Net Shares Purchased by Insiders−70k−35k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

PHIO Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New PHIO patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to PHIO from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from PHIO’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
85.59
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
18
Sells
0
Buy Value
$146.83K
Distinct Buyers
4

Insider Score Trend Over Time

+20.6 since Sep 8
0255075100Sep 8 — Insider Score 41.4Sep 9 — Insider Score 41.2Sep 10 — Insider Score 39.9Sep 11 — Insider Score 39.6Sep 12 — Insider Score 39.3Sep 13 — Insider Score 39.3Sep 14 — Insider Score 37.2Sep 15 — Insider Score 36.5Sep 16 — Insider Score 35.1Sep 17 — Insider Score 50.1Sep 18 — Insider Score 49.7Sep 19 — Insider Score 49.5Sep 20 — Insider Score 49.5Sep 21 — Insider Score 49.4Sep 22 — Insider Score 48.7Sep 23 — Insider Score 48.1Sep 24 — Insider Score 56.0Sep 25 — Insider Score 60.2Sep 26 — Insider Score 63.5Sep 27 — Insider Score 63.4Sep 28 — Insider Score 63.3Sep 29 — Insider Score 63.1Sep 30 — Insider Score 63.0Oct 1 — Insider Score 65.6Oct 2 — Insider Score 39.0Oct 3 — Insider Score 65.4Oct 4 — Insider Score 65.2Oct 5 — Insider Score 65.3Oct 6 — Insider Score 65.1Oct 7 — Insider Score 65.0Oct 8 — Insider Score 65.1Oct 9 — Insider Score 65.1Oct 10 — Insider Score 65.0Oct 11 — Insider Score 65.2Oct 12 — Insider Score 65.2Oct 13 — Insider Score 65.1Oct 14 — Insider Score 65.0Oct 15 — Insider Score 64.9Oct 16 — Insider Score 64.8Oct 17 — Insider Score 64.7Oct 18 — Insider Score 64.8Oct 19 — Insider Score 64.7Oct 20 — Insider Score 64.6Oct 21 — Insider Score 64.5Oct 22 — Insider Score 64.5Oct 23 — Insider Score 64.5Oct 24 — Insider Score 64.5Oct 25 — Insider Score 64.4Oct 26 — Insider Score 64.4Oct 27 — Insider Score 64.4Oct 28 — Insider Score 64.5Oct 29 — Insider Score 64.2Oct 30 — Insider Score 63.6Oct 31 — Insider Score 63.6Nov 1 — Insider Score 63.6Nov 2 — Insider Score 63.5Nov 3 — Insider Score 63.4Nov 4 — Insider Score 63.1Nov 5 — Insider Score 62.5Nov 6 — Insider Score 62.0Sep 8Oct 7Nov 6

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.